MyFinsight
Home
Blog
About
Back
Income Statement
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)
source: myfinsight.com
Total comprehensive
loss
-$75,843K
(-540.03%↓ Y/Y)
Net income (loss)
-$75,488K
(-370.36%↓ Y/Y)
Foreign currency
translation adjustments
-$355K
(-108.42%↓ Y/Y)
Net loss before
income tax expense
-$75,413K
(-371.86%↓ Y/Y)
Income tax benefit
(expense)
$75K
(11.94%↑ Y/Y)
Fair value
adjustment for warrants
-$4,507K
(-200.96%↓ Y/Y)
Interest income
$584K
(87.78%↑ Y/Y)
Other (expense)
income, net
$152K
(624.14%↑ Y/Y)
Loss from operations
-$79,782K
(-665.15%↓ Y/Y)
Warrant issuance costs
$874K
(0.23%↑ Y/Y)
Total operating
expenses
$79,782K
(665.15%↑ Y/Y)
Gain on orphai
acquisition
$1,305K
Acquired in-process
research and development
$59,000K
General and
administrative
$16,626K
(397.49%↑ Y/Y)
Research and development
$5,461K
(-16.66%↓ Y/Y)
Back